| Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability S Srivastava, JG Pasipanodya, C Meek, R Leff, T Gumbo The Journal of infectious diseases 204 (12), 1951-1959, 2011 | 343 | 2011 |
| Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy JG Pasipanodya, S Srivastava, T Gumbo Clinical Infectious Diseases 55 (2), 169-177, 2012 | 290 | 2012 |
| The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance AM Schmalstieg, S Srivastava, S Belkaya, D Deshpande, C Meek, R Leff, ... Antimicrobial agents and chemotherapy 56 (9), 4806-4815, 2012 | 211 | 2012 |
| Efflux-Pump—Derived Multiple Drug Resistance to Ethambutol Monotherapy in Mycobacterium tuberculosis and the Pharmacokinetics and Pharmacodynamics of … S Srivastava, S Musuka, C Sherman, C Meek, R Leff, T Gumbo The Journal of infectious diseases 201 (8), 1225-1231, 2010 | 158 | 2010 |
| Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis K Dheda, L Lenders, G Magombedze, S Srivastava, P Raj, E Arning, ... American journal of respiratory and critical care medicine 198 (9), 1208-1219, 2018 | 150 | 2018 |
| Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence JG Pasipanodya, D Ogbonna, BE Ferro, G Magombedze, S Srivastava, ... Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 01206-17, 2017 | 146 | 2017 |
| Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests S Swaminathan, JG Pasipanodya, G Ramachandran, AK Hemanth Kumar, ... Clinical Infectious Diseases 63 (suppl_3), S63-S74, 2016 | 127 | 2016 |
| Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions AA Ordonez, H Wang, G Magombedze, CA Ruiz-Bedoya, S Srivastava, ... Nature medicine 26 (4), 529-534, 2020 | 112 | 2020 |
| Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis S Srivastava, G Magombedze, T Koeuth, C Sherman, JG Pasipanodya, ... Antimicrobial agents and chemotherapy 61 (8), 10.1128/aac. 00751-17, 2017 | 107 | 2017 |
| Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis D Deshpande, JG Pasipanodya, SG Mpagama, P Bendet, S Srivastava, ... Clinical Infectious Diseases 67 (suppl_3), S293-S302, 2018 | 104 | 2018 |
| Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment MS Bolhuis, OW Akkerman, MGG Sturkenboom, S Ghimire, S Srivastava, ... Clinical Infectious Diseases 67 (suppl_3), S327-S335, 2018 | 83 | 2018 |
| Antibiotic Susceptibility of Helicobacter pylori Clinical Isolates: Comparative Evaluation of Disk-Diffusion and E-Test Methods KK Mishra, S Srivastava, A Garg, A Ayyagari Current microbiology 53, 329-334, 2006 | 81 | 2006 |
| Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis D Deshpande, S Srivastava, M Chapagain, G Magombedze, KR Martin, ... Science Advances 3 (8), e1701102, 2017 | 77 | 2017 |
| Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease BE Ferro, S Srivastava, D Deshpande, JG Pasipanodya, D van Soolingen, ... Antimicrobial agents and chemotherapy 60 (5), 2895-2900, 2016 | 70 | 2016 |
| Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? S Srivastava, CA Peloquin, G Sotgiu, GB Migliori European Respiratory Journal 42 (6), 1449-1453, 2013 | 70 | 2013 |
| Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular … D Deshpande, S Srivastava, C Meek, R Leff, T Gumbo Antimicrobial agents and chemotherapy 54 (5), 1728-1733, 2010 | 70 | 2010 |
| Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex disease JG Pasipanodya, D Ogbonna, D Deshpande, S Srivastava, T Gumbo Journal of Antimicrobial Chemotherapy 72 (suppl_2), i3-i19, 2017 | 69 | 2017 |
| Clinical standards for the dosing and management of TB drugs JWC Alffenaar, SL Stocker, LD Forsman, A Garcia-Prats, SK Heysell, ... The International Journal of Tuberculosis and Lung Disease 26 (6), 483-499, 2022 | 64 | 2022 |
| Nucleotide Polymorphism Associated with Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis S Srivastava, A Garg, A Ayyagari, KK Nyati, TN Dhole, SK Dwivedi Current microbiology 53, 401-405, 2006 | 63 | 2006 |
| Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection D Deshpande, S Srivastava, C Meek, R Leff, GS Hall, T Gumbo Antimicrobial agents and chemotherapy 54 (6), 2534-2539, 2010 | 60 | 2010 |
Jotam G. Pasipanodya, MDVanderbilt University Medical Center (VUMC)Verified email at vumc.org
